WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces the reception of three esteemed International Organization for Standardization (ISO) certifications at its Ireland facility.…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) has initiated dosing for the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has revealed the findings from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study, assessing the effectiveness and safety…
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to…
AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell…
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion regarding the expansion…
Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Reblozyl® (luspatercept) for…
Celltrion presented encouraging findings from the extensive LIBERTY studies, including LIBERTY-CD 1 and LIBERTY-UC 2, focusing on patients with Alzheimer’s disease, Crohn’s disease (CD), or moderately to severely active ulcerative…
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has revealed plans to present findings from four studies examining apraglutide in adults diagnosed with short bowel syndrome with…
Bristol Myers Squibb (NYSE: BMY) has confirmed the conclusion of its tender offer, initially announced, to acquire all outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock at a price…
The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets…
Sanofi’s Board of Directors has announced its intentions for the upcoming General Shareholder Meeting on April 30, 2024. The board proposes the renewal of Rachel Duan and Lise Kingo’s terms,…